Systematic review of drug therapy for chorea in NXK2‐1‐related disorders: Efficacy and safety evidence from case studies and series

• Published in: European journal of neurology Vol. 30; no. 12; pp. 3928 - 3948
• Main Authors: Nou‐Fontanet, Laia, Martín‐Gómez, Carmen, Isabel‐Gómez, Rebeca, Bachoud‐Lévi, Anne‐Catherine, Zorzi, Giovanna, Capuano, Alessandro, Blasco‐Amaro, Juan Antonio, Ortigoza‐Escobar, Juan Darío
• Format: Journal Article
• Language: English
• Published: Oxford John Wiley & Sons, Inc 01.12.2023
• Subjects: Abnormalities; Carbamazepine; Chorea; clinical guideline; Clonazepam; Drug therapy; Genetic screening; Haloperidol; Heterogeneity; Levodopa; Methylphenidate; Neurological diseases; NKX2‐1; Patients; Propranolol; Risperidone; Signs and symptoms; Systematic review; Tetrabenazine; Topiramate; Trihexyphenidyl; Valproic acid
• ISSN: 1351-5101; 1468-1331
• DOI: 10.1111/ene.16038

Background The NKX2‐1‐related disorders (NKX2‐1‐RD) is a rare disorder characterized by choreiform movements along with respiratory and endocrine abnormalities. The European Reference Network of Rare Neurological Disorders funded by the European Commission conducted a systematic review to assess drug treatment of chorea in NKX2‐1‐RD, aiming to provide clinical recommendations for its management. Methods A systematic pairwise review using various databases, including MEDLINE, Embase, Cochrane, CINAHL, and PsycInfo, was conducted. The review included patients diagnosed with chorea and NKX2‐1‐RD genetic diagnosis, drug therapy as intervention, no comparator, and outcomes of chorea improvement and adverse events. The methodological quality of the studies was assessed, and the study protocol was registered in PROSPERO. Results Of the 1417 studies examined, 28 studies met the selection criteria, consisting of 68 patients. The studies reported 22 different treatments for chorea, including carbidopa/levodopa, tetrabenazine, clonazepam, methylphenidate, carbamazepine, topiramate, trihexyphenidyl, haloperidol, propranolol, risperidone, and valproate. No clinical improvements were observed with carbidopa/levodopa, tetrabenazine, or clonazepam, and various adverse effects were reported. However, most patients treated with methylphenidate experienced improvements in chorea and reported only a few negative effects. The quality of evidence was determined to be low. Conclusions The management of chorea in individuals with NKX2‐1‐RD presents significant heterogeneity and lack of clarity. While the available evidence suggests that methylphenidate may be effective in improving chorea symptoms, the findings should be interpreted with caution due to the limitations of the studies reviewed. Nonetheless, more rigorous and comprehensive studies are necessary to provide sufficient evidence for clinical recommendations.